Denali Therapeutics Inc. (DNLI)
NASDAQ
19.16
-0.12 (-0.62%)
Closed
Oct 7, 2026
Day's Range
18.8919.43
52 wk Range
13.7527.30
Financial Statements - DNLI - Denali Therapeutics Inc.
Revenue
0
Net Income
-512.54M▼ 21.2%
EBITDA
-540.53M▼ 6.5%
Free Cash Flow
-422.10M▼ 16.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 330.53M | 108.46M | 48.66M | 335.65M |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -555.34M | -501.87M | -196.69M | -340.74M | -295.75M | 62.71M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | 14.53M | - | - | - | - |
| Pre Tax Income | -512.43M | -422.70M | -145.19M | -325.97M | -291.15M | 71.95M |
| Income Tax | 102K | 68K | 30K | 21K | -575K | 823K |
| Net Income | -512.54M | -422.77M | -145.22M | -325.99M | -290.58M | 71.13M |
| EPS Basic | -2.97 | -2.57 | -1.06 | -2.6 | -2.39 | 0.65 |
| EPS Diluted | -2.97 | -2.57 | -1.06 | -2.6 | -2.39 | 0.63 |
| Basic Shares Outstanding | 172.64M | 164.47M | 137.37M | 125.53M | 121.52M | 108.97M |
| Diluted Shares Outstanding | 172.64M | 164.47M | 137.37M | 125.53M | 121.52M | 108.97M |
| Ebit | -555.34M | -501.87M | -196.69M | -340.74M | -295.75M | 62.71M |
| Ebitda | -540.53M | -507.42M | -179.97M | -330.36M | -287.15M | 71.24M |
| Net Income Continuous Operations | -512.54M | -422.77M | -145.22M | -325.99M | -290.58M | 71.13M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
